Latest Capital Raisings News

Broken Hill Mines Limited posted a $48.8 million loss for FY2026, driven by acquisition-related costs and re-compliance expenses, despite a 56% revenue increase reflecting production growth at Rasp and Pinnacles mines.

Austral Gold nearly doubled its gold equivalent production in the first half of 2026, driven by the Casposo restart and Guanaco operations, delivering a US$15.5 million net profit and extending Guanaco’s mine life to 14 years.

Saluda Medical delivered FY26 revenue of US$90.2 million, beating guidance with strong US and international growth, while reporting a flat net loss of US$149.6 million amid ongoing heavy investment. The company’s FDA approval of its CAP24 paddle lead opens a new US surgical market segment.

Weebit Nano surged to record revenue of $15.3 million in FY26, fueled by key licensing deals and product tape-outs, while investing heavily in R&D and AI initiatives. Despite a $54.9 million loss, a $102 million capital raise leaves the company well-positioned for growth.

Swift TV Ltd advanced its commercial rollout with 7,190 devices sold and secured key technology certifications in FY26, while navigating a 22% revenue decline due to legacy contract wind-downs. The company delivered positive EBITDA and raised $2.3 million to fund growth initiatives.

Elevra Lithium posted a $44 million profit in FY26 after merging Sayona Mining and Piedmont Lithium, overcoming temporary mining challenges and securing full funding for the North American Lithium expansion.

Rua Bioscience's FY26 results highlight a 71% surge in customer revenue driven by international expansion, yet the company continues to face significant losses and going concern risks.

Comvita Limited has swung back to profitability in FY26, reporting $7.7 million net profit after a $40.5 million capital raise that brought Southeast Asian consumer giant F&N Ventures on board with a near 20% stake.

Green & Gold Minerals posted a $886,828 loss for FY2026 amid a transformative year marked by its ASX listing and expansion into base metals exploration with the Herberton acquisition.

Almasar Minerals Limited (ASX:AMK) is launching an IPO to fund early-stage exploration across five licences in Saudi Arabia’s Arabian Shield, targeting gold and copper mineralisation.

Rhythm Biosciences marked its transition to commercialisation with first sales of ColoSTAT® and geneType™ tests, despite a 55% increase in loss to $5.93 million. The company expanded market access and secured manufacturing agreements, while NHS England began evaluating ColoSTAT® for bowel cancer screening.

Beonic Limited grew revenue by 5.2% to $23.3 million in FY26, halving its loss and achieving positive operating cash flow, underpinned by a landmark Moroccan airport contract and product innovation.